Improving management of patients with advanced cancer

References

• ColemanREBisphosphonates: clinical experienceOncologist20049Suppl 4142715459426
   PubMed Web of Science ®Google Scholar
• FitchMMaxwellCRyanCLothmanHDrudge-CoatesLCostaLBone metastases from advanced cancers: clinical implications and treatment optionsClin J Oncol Nurs200913670171019948468
   PubMed Web of Science ®Google Scholar
• LiptonABisphosphonate therapy in the oncology settingExpert Opin Emerg Drugs20038246948814662000
   PubMedGoogle Scholar
• ColemanREMetastatic bone disease: clinical features, pathophysiology and treatment strategiesCancer Treat Rev200127316517611417967
   PubMed Web of Science ®Google Scholar
• LiptonATreatment of bone metastases and bone pain with bisphosphonatesSupport Cancer Ther2007429210018632473
   PubMedGoogle Scholar
• Aredia [package insert]East Hanover, NJNovartis Pharmaceuticals Corporation2008
   Google Scholar
• Zometa [package insert]East Hanover, NJNovartis Pharmaceuticals Corporation2009
   Google Scholar
• Ostac [package insert]Nutley, NJHoffmann-La Roche2004
   Google Scholar
• Bondronat [summary of product characteristics]Welwyn Garden City, UKRoche Products Ltd2007
   Google Scholar
• PavlakisNSchmidtRStocklerMBisphosphonates for breast cancerCochrane Database Syst Rev20053CD00347416034900
   PubMed Web of Science ®Google Scholar
• AaproMAbrahamssonPABodyJJGuidance on the use of bisphosphonates in solid tumours: recommendations of an international expert panelAnn Oncol200819342043217906299
   PubMed Web of Science ®Google Scholar
• KohnoNAogiKMinamiHZoledronic acid significantly reduces skeletal complications compared with placebo in Japanese women with bone metastases from breast cancer: a randomized, placebo-controlled trialJ Clin Oncol200523153314332115738536
   PubMed Web of Science ®Google Scholar
• HortobagyiGNTheriaultRLPorterLEfficacy of pamidronate in reducing skeletal complications in patients with breast cancer and lytic bone metastases. Protocol 19 Aredia Breast Cancer Study GroupN Engl J Med199633524178517918965890
   PubMed Web of Science ®Google Scholar
• HortobagyiGNTheriaultRLLiptonALong-term prevention of skeletal complications of metastatic breast cancer with pamidronate. Protocol 19 Aredia Breast Cancer Study GroupJ Clin Oncol1998166203820449626201
   PubMed Web of Science ®Google Scholar
• BodyJJDielIJLichinitserMRIntravenous ibandronate reduces the incidence of skeletal complications in patients with breast cancer and bone metastasesAnn Oncol20031491399140512954579
   PubMed Web of Science ®Google Scholar
• BodyJJDielIJBellROral ibandronate improves bone pain and preserves quality of life in patients with skeletal metastases due to breast cancerPain2004111330631215363874
   PubMed Web of Science ®Google Scholar
• KristensenBEjlertsenBGroenvoldMHeinSLoftHMouridsenHTOral clodronate in breast cancer patients with bone metastases: a randomized studyJ Intern Med19992461677410447227
   PubMed Web of Science ®Google Scholar
• PatersonAHPowlesTJKanisJAMcCloskeyEHansonJAshleySDouble-blind controlled trial of oral clodronate in patients with bone metastases from breast cancerJ Clin Oncol199311159658418243
   PubMed Web of Science ®Google Scholar
• Tubiana-HulinMBeuzebocPMauriacL[Double-blinded controlled study comparing clodronate versus placebo in patients with breast cancer bone metastases]Bull Cancer200188770170711495824
   PubMed Web of Science ®Google Scholar
• MajorPPCookRJChenBLZhengMSurvival-adjusted multiple-event analysis for the evaluation of treatment effects of zoledronic acid in patients with bone metastases from solid tumorsSupport Cancer. Ther20052423424018628179
   PubMedGoogle Scholar
• ColemanRESkeletal complications of malignancyCancer1997808 Suppl158815949362426
   PubMed Web of Science ®Google Scholar
• PayneRPharmacologic management of bone pain in the cancer patientClin J Pain19895Suppl 2S43S49 discussion follows.2520440
   PubMed Web of Science ®Google Scholar
• ReichCDAdvances in the treatment of bone metastasesClin J Oncol Nurs20037664164614705479
   PubMedGoogle Scholar
• BarnettMLHypercalcemiaSemin Oncol Nurs199915319020110461704
   PubMedGoogle Scholar
• MaxwellCRole of the nurse in preserving patients’ independenceEur J Oncol Nurs200711Suppl 2S38S4117768093
   PubMed Web of Science ®Google Scholar
• MaxwellCSwiftRGoodeMDoaneLRogersMAdvances in supportive care of patients with cancer and bone metastases: nursing implications of zoledronic acidClin J Oncol Nurs20037440340812929273
   PubMedGoogle Scholar
• RosenLSGordonDKaminskiMZoledronic acid versus pamidronate in the treatment of skeletal metastases in patients with breast cancer or osteolytic lesions of multiple myeloma: a phase III, double-blind, comparative trialCancer J20017537738711693896
   PubMed Web of Science ®Google Scholar
• DielIJBergnerRGrotzKAAdverse effects of bisphosphonates: current issuesJ Support Oncol200751047548218240669
   PubMedGoogle Scholar
• BerensonJRRosenLSHowellAZoledronic acid reduces skeletal-related events in patients with osteolytic metastasesCancer20019171191120011283917
   PubMed Web of Science ®Google Scholar
• HoffAOTothBBAltundagKFrequency and risk factors associated with osteonecrosis of the jaw in cancer patients treated with intravenous bisphosphonatesJ Bone Miner Res200823682683618558816
   PubMed Web of Science ®Google Scholar
• McArthurHLEstiloCHurynJOsteonecrosis of the jaw (ONJ) among intravenous (IV) bisphosphonate- and/or bevacizumab-treated patients (pts) at Memorial Sloan-Kettering Cancer Center (MSKCC). [abstract]J Clin Oncol200826Suppl 15523s Abstract 9588.
   Web of Science ®Google Scholar
• HenryDvon MoosRVadhan-RajSA double-blind, randomized study of denosumab versus zoledronic acid for the treatment of bone metastases in patients with advanced cancer (excluding breast and prostate cancer) or multiple myeloma. [abstract]Eur J Cancer Suppl20097311 Abstract 20LBA.
   Web of Science ®Google Scholar
• StopeckATLiptonABodyJJDenosumab Compared With Zoledronic Acid for the Treatment of Bone Metastases in Patients With Advanced Breast Cancer: A Randomized, Double-Blind StudyJ Clin Oncol2010118 [Epub ahead of print].
   Web of Science ®Google Scholar
• ColemanRBundredNde BoerRImpact of zoledronic acid in postmenopausal women with early breast cancer receiving adjuvant letrozole: Z-FAST, ZO-FAST, and E-ZO-FAST. [abstract]Cancer Res200969Suppl 24733s Abstract 4082.
   Web of Science ®Google Scholar
• DimopoulosMAKastritisEBamiaCReduction of osteonecrosis of the jaw (ONJ) after implementation of preventive measures in patients with multiple myeloma treated with zoledronic acidAnn Oncol200920111712018689864
   PubMed Web of Science ®Google Scholar
• RipamontiCIManiezzoMCampaTDecreased occurrence of osteonecrosis of the jaw after implementation of dental preventive measures in solid tumour patients with bone metastases treated with bisphosphonates The experience of the National Cancer Institute of MilanAnn Oncol200920113714518647964
   PubMed Web of Science ®Google Scholar
• ChowEBottomleyAUnderstanding the EORTC QLQ-BM22, the module for patients with bone metastasesExpert Rev Pharmacoecon Outcomes Res20099546146519817529
   PubMedGoogle Scholar
• ChowEHirdAVelikovaGThe European Organisation for Research and Treatment of Cancer Quality of Life Questionnaire for patients with bone metastases: the EORTC QLQ-BM22Eur J Cancer20094571146115219097882
   PubMed Web of Science ®Google Scholar
• SchumacherKLKoresawaSWestCThe usefulness of a daily pain management diary for outpatients with cancer-related painOncol Nurs Forum20022991304131312370700
   PubMedGoogle Scholar
• WardleyADavidsonNBarrett-LeePZoledronic acid significantly improves pain scores and quality of life in breast cancer patients with bone metastases: a randomised, crossover study of community vs hospital bisphosphonate administrationBr J Cancer200592101869187615870721
   PubMed Web of Science ®Google Scholar
• CostaLBadiaXChowELiptonAWardleyAImpact of skeletal complications on patients’ quality of life, mobility, and functional independenceSupport Care Cancer200816887988918392862
   PubMed Web of Science ®Google Scholar
• WongRWiffenPJBisphosphonates for the relief of pain secondary to bone metastasesCochrane Database Syst Rev20022CD00206812076438
   PubMedGoogle Scholar
• Drudge-CoatesLThompsonPMMuirGHBurden of bone metastases from renal cell carcinoma: zoledronic acid and functional independence[poster]Societe Internationale d’Urologie (SIU) World Uro-Oncology Update2008 Nov 19–22Santiago, Chile Abstract UP-18.
   Google Scholar
• MangiapaneSHoerAGotheHBarghoutVHaeusslerBHigher persistency with i.v. bisphosphonates in patients with bone metastasis. [abstract]J Clin Oncol200624Suppl 18698s Abstract 18623.
   Google Scholar
• RabendaVHiligsmannMReginsterJYPoor adherence to oral bisphosphonate treatment and its consequences: a review of the evidenceExpert Opin Pharmacother200910142303231519640210
   PubMed Web of Science ®Google Scholar
• FallowfieldLStebbingJBraybrookeJLangridgeCJenkinsVThe preferences and experiences of different bisphosphonate treatments in women with breast cancerPsycho-oncology2010524 [Epub ahead of print].
   Web of Science ®Google Scholar
• HatoumHTLinSJSmithMRBarghoutVLiptonAZoledronic acid and skeletal complications in patients with solid tumors and bone metastases: analysis of a national medical claims databaseCancer200811361438144518720527
   PubMed Web of Science ®Google Scholar
• FitchMIMaxwellCBisphosphonate therapy for metastatic bone disease: the pivotal role of nurses in patient educationOncol Nurs Forum200835470971318591175
   PubMed Web of Science ®Google Scholar
• ColemanREWinterMCCameronDThe effects of adding zoledronic acid to neoadjuvant chemotherapy on tumour response: exploratory evidence for direct anti-tumour activity in breast cancerBr J Cancer201010271099110520234364
   PubMed Web of Science ®Google Scholar
• MorganGDaviesFGregoryWEvaluating the effects of zoledronic acid (ZOL) on overall survival (OS) in patients (Pts) with multiple myeloma (MM): Results of the Medical Research Council (MRC) Myeloma IX study. [abstract]J Clin Oncol201029Suppl 15578s Abstract 8021.
   Google Scholar
• ZaghloulMSBoutrusREl-HossienyHKaderYAEl-AttarINazmyMA prospective, randomized, placebo-controlled trial of zoledronic acid in bony metastatic bladder cancerInt J Clin Oncol201015438238920354750
   PubMed Web of Science ®Google Scholar
• ZarogoulidisKBoutsikouEZarogoulidisPThe impact of zoledronic acid therapy in survival of lung cancer patients with bone metastasisInt J Cancer200912571705170919521984
   PubMed Web of Science ®Google Scholar
• BodyJ-JCookRCostaLPossible survival benefits from zoledronic acid treatment in patients with bone metastases from solid tumors and poor prognostic features. [poster]The IX International Meeting on Cancer Induced Bone Disease2009 Oct 28–31Arlington, VA Poster 71.
   Google Scholar
• CostaLCookRBodyJ-JZoledronic acid treatment delays disease progression and improves survival in patients with bone metastases from solid tumors and elevated levels of bone resorption. [poster]The IX International Meeting on Cancer Induced Bone Disease2009 Oct 28–31Arlington, VA Poster 50.
   Google Scholar
• GnantMMlineritschBSchippingerWEndocrine therapy plus zoledronic acid in premenopausal breast cancerN Engl J Med2009360767969119213681
   PubMed Web of Science ®Google Scholar
• RennertGPinchevMRennertHSUse of bisphosphonates and risk of postmenopausal breast cancerJ Clin Oncol201028223577358120567021
   PubMed Web of Science ®Google Scholar
• NewcombPATrentham-DietzAHamptonJMBisphosphonates for osteoporosis treatment are associated with reduced breast cancer riskBr J Cancer2010102579980220160722
   PubMed Web of Science ®Google Scholar
• ChlebowskiRTChenZCauleyJAOral bisphosphonate use and breast cancer incidence in postmenopausal womenJ Clin Oncol201028223582359020567009
   PubMed Web of Science ®Google Scholar